Aerie Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($3.17) Per Share (AERI)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Stock analysts at Cantor Fitzgerald lowered their FY2017 EPS estimates for Aerie Pharmaceuticals in a research report issued on Wednesday. Cantor Fitzgerald analyst E. Piros now expects that the company will earn ($3.17) per share for the year, down from their previous estimate of ($2.99). Cantor Fitzgerald currently has a “Overweight” rating and a $62.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aerie Pharmaceuticals’ FY2018 earnings at ($2.17) EPS.
Several other equities analysts have also recently weighed in on AERI. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th. HC Wainwright set a $69.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $66.08.
Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at 55.25 on Monday. The company’s 50 day moving average price is $54.13 and its 200 day moving average price is $48.67. The stock’s market capitalization is $2.01 billion. Aerie Pharmaceuticals has a one year low of $18.52 and a one year high of $59.50.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02.
A number of large investors have recently modified their holdings of AERI. Quantbot Technologies LP bought a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at about $107,000. Ameritas Investment Partners Inc. bought a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at about $108,000. BNP Paribas Arbitrage SA increased its stake in shares of Aerie Pharmaceuticals by 2,711.4% in the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares during the period. BlueCrest Capital Management Ltd bought a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at about $202,000. Finally, Amalgamated Bank bought a new stake in shares of Aerie Pharmaceuticals during the second quarter valued at about $204,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.